Mitochondria are crucial in many basic cellular processes. Therefore, somatic mutations in mitochondrial DNA (mtDNA) have been regarded as a hallmark of cancer. Recent advance in mtDNA research have shown that inherited genetic variations, including both single nucleotide polymorphisms (SNPs) and copy number variations, are also related to certain human cancers. However, so far, there is little known about the role of mtNDA heteroplasmies, another type of mtDNA variation, in human cancer. Heteroplasmy, which has been widely observed in mitochondrial genome, is defined as the coexistence of wild-type and variant mtDNA in the same cell and tissue. In mitochondrial related diseases, the amount of adverse variant mtDNA in a cell, called the heteroplasmy level, is an important factor in determining the amount of mitochondrial dysfunction and therefore the disease severity. In the case of human cancer, high heteroplasmy level might reflect high levels of genomic instability and mitochndrial dysfunction, and thereby increased risk of cancer. mtDNA heteroplasmy might be extremely relevant to breast cancer because oxidative stress has been suggested to play a significant role in breast cancer etiology. Considerable effort has been made to discover breast cancer susceptibility genes. However, few have been identified to date. The dilemma might be due to the fact that some of the susceptibility alleles might not reside in nuclear DNA, but in mtDNA. In my pilot study of heteroplasmy in the hypervariable (HV) regions of mtDNAs, we found the presence of length heteroplasmies in both of the HV1 and HV2 regions was associated with increased risk of breast cancer, suggesting that mtDNA heteroplasmy may be associated with breast cancer. Current research on mtDNA heteroplasmy and human diseases is significantly hindered by the lack of sensitive methods to detect mtDNA heteroplasmy. Traditional Sanger capillary sequencing not only needs significant amount of labor/time to manually inspect data but also can only detect common mtDNA heteroplasmy (more than 20-25%). Therefore, there are still large amount of mtDNA heteroplasmies are left undetected. Some of them might have significant impact on mitochondrial functions and consequently human diseases. Recent development of Next Generation Sequencing (NGS) may dramatically advance our knowledge on mtDNA heteroplasmy. NGS methods can generate vast amounts of sequencing data so it is able to detect mtDNA heteroplasmy even at low levels with high confidence. In a recent study from Vogelstein's group, using massive parallel sequencing, they detected a significant amount of novel variants and observed widespread heteroplasmy in the mtDNA of normal human cells.

Public Health Relevance

Our goal is to understand the relationship between mitochondrial and breast cancer. The objective here is to determine the roles of mtDNA heteroplasmy, a largely understudied mtDNA variations, in the development of breast cancer. Our central hypothesis is that the presence of heteroplasmy of mtDNAs is an indicator of mitochondrial genome instability and mtDNA malfunction and, thus, may be associated with increased breast cancer risk.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Small Research Grants (R03)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Verma, Mukesh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Public Health & Prev Medicine
Schools of Medicine
United States
Zip Code
Shen, Jie; Wan, Jie; Song, Renduo et al. (2015) Peripheral blood mitochondrial DNA copy number, length heteroplasmy and breast cancer risk: a replication study. Carcinogenesis 36:1307-13
Zhao, Hua; Shen, Jie; Hu, Qiang et al. (2014) Effects of preanalytic variables on circulating microRNAs in whole blood. Cancer Epidemiol Biomarkers Prev 23:2643-8
Shen, Jie; Hu, Qiang; Schrauder, Michael et al. (2014) Circulating miR-148b and miR-133a as biomarkers for breast cancer detection. Oncotarget 5:5284-94